ReviewFrontiers in immunology2022
Regulatory T Cells, a Viable Target Against Airway Allergic Inflammatory Responses in Asthma.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- A molecular systems architecture of asthma.Frontiers in immunology · 2026Pooled it
- A Comprehensive Review of Natural Products Against Allergic Rhinitis and Asthma: From Sensitization to Chronic Remodeling.International journal of molecular sciences · 2026Review
- Multi-Kingdom Fecal Microbiota Alterations in Horses with Severe Equine Asthma.Microorganisms · 2026Article
- Multifaceted mechanistic exploration ofFrontiers in cell and developmental biology · 2026Article
- FGF21 Exacerbates Obesity-Induced Airway Hyperresponsiveness and FGFR1-Dependent Mast Cell Activation in Mice.Journal of inflammation research · 2026Article
- Flavonoids as potential anti-asthmatic agents.Frontiers in immunology · 2026Review
- Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives.Frontiers in immunology · 2026Review
- Signaling pathways of marine-derived natural products on lung injury: from theFrontiers in pharmacology · 2025Review
- Exogenous acetate mitigates later enhanced allergic airway inflammation in a menopausal mouse model.Frontiers in cellular and infection microbiology · 2025Article
- LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells.The European respiratory journal · 2024Article
- Disease Severity and Cytokine Expression in the Rhinovirus-Induced First Wheezing Episode.Viruses · 2024Article
- Evaluating the Toxocara cati extract as a therapeutic agent for allergic airway inflammation.Immunity, inflammation and disease · 2024Article
- Engineering nanoparticle therapeutics for food allergy.The Journal of allergy and clinical immunology · 2024Review
- Editorial: Exploring the role of adaptive immunity in chronic airway respiratory diseases.Frontiers in allergy · 2024Article
- Regulatory T cells in allergic inflammation.Seminars in immunology · 2023Review
- Tyndallized Bacteria Preferentially Induce Human Macrophage M1 Polarization: An Effect Useful to Balance Allergic Immune Responses and to Control Infections.Antibiotics (Basel, Switzerland) · 2023Article
- Ferroptosis-related genes are involved in asthma and regulate the immune microenvironment.Frontiers in pharmacology · 2023Article
- Plexin B1 controls Treg numbers, limits allergic airway inflammation, and regulates mucins.Frontiers in immunology · 2023Article
- How GRAIL controls Treg function to maintain self-tolerance.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a multifactorial disorder characterized by the airway chronic inflammation, hyper-responsiveness (AHR), remodeling, and reversible obstruction. Although asthma is known as a heterogeneous group of diseases with various clinical manifestations, recent studies suggest that more than half of the clinical cases are ''T helper type 2 (Th2)-high'' type, whose pathogenesis is driven by Th2 responses to an inhaled allergen from the environmental exposures. The intensity and duration of inflammatory responses to inhaled allergens largely depend on the balance between effector and regulatory cells, but many questions regarding the mechanisms by which the relative magnitudes of these opposing forces are remained unanswered. Regulatory T cells (Tregs), which comprise diverse subtypes with suppressive function, have long been attracted extensive attention owing to their capability to limit the development and progression of allergic diseases. In this review we seek to update the recent advances that support an essential role for Tregs in the induction of allergen tolerance and attenuation of asthma progression once allergic airway inflammation established. We also discuss the current concepts about Treg induction and Treg-expressed mediators relevant to controlling asthma, and the therapies designed based on these novel insights against asthma in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.